Keri Daniel, Walker Matt, Singh Isha, Nishikawa Kyle, Garces Fernando
Department of Protein Therapeutics, Research, Gilead Research, 324 Lakeside Dr, Foster City, CA 94404, USA.
Antib Ther. 2023 Dec 8;7(1):37-52. doi: 10.1093/abt/tbad027. eCollection 2024 Jan.
Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting such as with monoclonal antibodies or cytokines alone. However, the approach to the development of these multispecific molecules has been met with numerous road bumps, which suggests that a new workflow for multispecific molecules is required. The investigation of the molecular basis that mediates the successful assembly of the building blocks into non-native quaternary structures will lead to the writing of a playbook for multispecifics. This is a must do if we are to design workflows that we can control and in turn predict success. Here, we reflect on the current state-of-the-art of therapeutic biologics and look at the building blocks, in terms of proteins, and tools that can be used to build the foundations of such a next-generation workflow.
多特异性抗体可识别位于同一或不同靶标上的两个或更多表位。通过蛋白质设计赋予的这种额外能力,使这些人造分子能够满足单靶点疗法(如单独使用单克隆抗体或细胞因子)无法满足的未被满足的医疗需求。然而,这些多特异性分子的开发方法遇到了许多阻碍,这表明需要一种新的多特异性分子工作流程。对介导构建模块成功组装成非天然四级结构的分子基础进行研究,将有助于编写多特异性分子的操作指南。如果我们要设计出可控且能预测成功的工作流程,这是必须要做的。在此,我们反思治疗性生物制品的当前技术水平,并从蛋白质角度审视构建模块以及可用于构建这种下一代工作流程基础的工具。